THE ASSOCIATION WITH THE AUTONOMIC NERVOUS SYSTEM FINDINGS AND PREDOMINANT SIDE OF ONSET OF IDIOPATIC PARKINSON’S DISEASE

Abstract

Idiopatic Parkinson’s Disease (iPD) is a neurodegenerative disorder which the motor and nonmotor symptoms are accompanied with. Non-motor features can be seen in every stage and can appear before motor findings arise. Autonomic dysfunction is one of the most prevalent non-motor features of iPD which includes enteric and bladder dysfunction, sexual dysfunction, sweating disorders, ortostatic hypotension. Not only because they seem very often but since they effect the quality of life of the patiens, non-motor symptoms have great importance. The assymetry of brain as a universal phenomenon describes the function of the whole nervous systhem. This assimetric involvement is also manifested in iPD studies clinically and neuropathologically. In this study we examined 30 İPD patients to investigate the association of asymmetry in iPD and autonomic nervous system involvement. Patients are göne through a detailed phusical and neurological examination. H&Y, UPDRS, MMT scores are enrolled. Autonomic symptoms are questionized with 12 items. When the outcomes are examined we saw that autonomic disorder severity increases with the term of disease as well as the severity of motor symptoms. Furthermore we came through that the autonomic symptoms can be seen from the early stages of the disease. The patients without bradikinesia had better responses to the therapy. The frequency of hallucination increased with the age and the severity of the disease. When the association with the side of onset of İPH symptoms and the autonomic involvement examined, which was the aim of this study, there was not a significant association but a week correlation.

Keywords

• Parkinson’s disease
• autonomic nervous system
• asymmetric involvement

References

1. 1. Ropper AH, Brown RH, Adams and Viktor‘s Principles of Neurology. 8. Baskı ed. 2006: Güneş Kitabevi. 915-925.
2. 2. Jankovich J, Shannon KM, Movement Disorders, in Neurology in Clinical Practice, D.R. Bradley WG, Fenicel GM, Jankovic J, Editor. 2008. p. 2087-2101
3. 3. Fahn S, Przedborski S, Parkinsonizm, in Merritt‘s Neurology, Rowland LP, Editor. 2008. p. 828-845.
4. 4. Fahn S, Jankovich J, Principles and Practice of Movement Disorders. 2008. Veri medikal yay.70-230.
5. 5. Iodice V, Loe D.A, Vichayanrat E, Mathias C.J, Cardiovasculer autonomic Disfunction in MSA and Parkinson‘s diseas: similarities and differences. J. Neurol Sci. 2011; 810: 183-188.
6. 6. Mehndiratta M, Garg R.K, Pandey S, Nonmotor Symptom Complex of Parkinson‘s Disease: an under-recognized entity. J Assoc Physicians İndia 2011; 59: 802-808.
7. 7. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ, Assessment of autonomic dysfunction inParkinson's disease: the SCOPA-AUT. Mov Disord, 2004. 19(11): 1306-12.
8. 8. Tolosa E, Gaig C, Santamaria J, Compta Y, Diagnosis and the premotor phase of Parkinson disease. Neurology, 2009. 72(7 Suppl): S12-20.

9. 9. Lyons KE, Pahwa R, The impact and management of nonmotor symptoms of Parkinson‘s disease, Am J Manag Care.2011 Oct; 17 Suppl. 12: S308-14.
10. 10. Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology, 2010;74(11):924–31.
11. 11. Braak H, del Tredici K, Rub U, de Vos R, Steur EJ, Braak E. Staging of brain pathology related to sporadic Parkinson‘s disease.Neurobiol Aging 2003;24:197-211.
12. 12. Micieli G, Tosi P, Marcheselli S, Cavallini A, Autonomic dysfunction in Parkinson's disease. Neurol Sci, 2003. 24 Suppl 1: S32-4.
13. 13. Gurevich T, Korczyn AD, Autonomic Disturbances in Parkinson's Disease, GalvezJimenez,N, Scientific Basis for the Treatment of Parkinson's Disease, Taylor & Francis, A.N. Dursun,Editor. 2005; 23: 333-345 14. Sethi K., Levodopa unresponsive symptoms in Parkinson disease. Mov Disord, 2008. 23 Suppl 3: S521-33.
14. 15. Akyüz G, Elektrodiyagnoz Otonom Sinir Sistemi Elektrofizyolojisi. 2003. 437-463.
15. 16. Ruth Djaldetti, İlan Ziv, The mystrey of motor asymmetry in Parkinson‘s disease, Lancet Neurol 2006; 5:796-802.
16. 17. Schestatsky P, Ehlers JA, Rieder CR, Gomes I, Evaluation of sympathetic skin response in Parkinson's disease. Parkinsonism Relat Disord, 2006. 12(8): 486-91.
17. 18. T. Holtgraves, P. McNamara ve ark,Linguistic correlates of asymmetric motor symptom severity in Parkinson‘s disease, Brain and Cognition 72,2010; 189-196.
18. 19. Hughes AJ, Daniel SE, Kilford L ve ark. Accuracy of clinical diagnosis of idiopathic Parkinson‟s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 55:181-184. 1992.
19. 20. Hoehn MM,Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967: 17: 427–442. 21. Gelb DJ,Oliver E,Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33–39.
20. 22. Djaldetti R,Shifrin A,Rogowski Z, et al. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology 2004; 62: 2171–2175.
21. 23. Friedman JH,Friedman H. Fatigue in Parkinson's disease: a nine-year follow-up. Mov Disord 2001; 16: 1120–1122.
22. 24. Djaldetti R,Melamed E,Gadoth N. Abnormal skin wrinkling in the less affected side in hemi-Parkinsonism—a possible test for sympathetic dysfunction in Parkinson's disease. Biomed Pharmacother 2001; 55: 475–478.
23. 25. Kempster PA, Gibb WRG, Stern GM, Lees AJ. Asymmetry of substantia nigra neuronal loss in Parkinson‘s disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry. 1989;52(1):72-76.
24. 26. Agid Y, Cervera P, Hirsch E, et al. Biochemistry of Parkinson‘s disease 28 years later: a critical review. Mov Disord. 1989;4(suppl 1):S126-S144.
25. 27. Marsden CD. Parkinson‘s disease. Lancet. 1990;335(8695): 948-952.
26. 28. Haaxma CA, Helmich RC, Borm GF, et al. Side of symptom onset affects motor dysfunction in Parkinson‘s disease. Neuroscience. 2010;170(4):1282-1285.
27. 29. Dethy S, van Blercom N, Damhaut P, et al. Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in parkinsonism. Mov Disord. 1998;13(2):275-280.
28. 30. Djaldetti R, Treves TA, Ziv I, et al. Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease. Neurol Sci. 2009;30(4):301-305.
29. 31. Djaldetti R, Lorberboym M, Karmon Y, et al. Residual striatal dopaminergic nerve terminals in very long-standing Parkinson‘s disease: a single photon emission computed tomography imaging study. Mov Disord. 2011;26(2):327-330.
30. 32. Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F]dopa PET findings in early Parkinson‘s disease. J Neurol Neurosurg Psychiatry 1995; 59:597-600.
31. 33. Cubo E, Martin PM, Martin-Gonzalez JA, Rodríguez-Blázquez C, Kulisevsky J, ELEP Group Members. Motor laterality asymmetry and nonmotor symptoms in Parkinson‘s disease. Mov Disord 2010;25:70e5.
32. 34. Cooper CA, Mikos AE, Wood MF, Kirsch-Darrow L, Jacobson CE, Okun MS, et al. Does laterality of motor impairment tell us something about cognition in Parkinson disease? Parkinsonism Relat Disord 2009;15:315-317.
33. 35. Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of non motor symptoms in Parkinson‘s disease in an international setting; study using non motor symptoms questionaire in 545 patients. Movment Disorders 2007; 22: 1623-9.
34. 36. Cubo E, Benito-Leon J, Coronell C, Armesto D. Clinical correlates of apathy in patients recently diagnosed with Parkinson‘s disease: the ANIMO study. Neuroepidemiology. 2012;38(1): 48-55.
35. 37. Liotti M, Mayberg HS. 2001. The role of functional neuroimaging in the neuropsychology of depression. J Clin Exp Neuropsychol 23: 121–136.
36. 38. P.Mc.Namara, K. Stavitsky et al, Mood, side of motor symptom onset and pain complaints in Parkinson‘s disease, Int J Geriatr Psychiatry 2010; 25: 519-524.
37. 39. Chaudhuri KR, Yates L, Martinez-Martin, P Curr, Review The non-motor symptom complex of Parkinson's disease: a comprehensive assessment is essential, Neurol Neurosci Rep. 2005 Jul; 5(4):275-83.
38. 40. Chaudhuri KR, Naidu Y J, Review Early Parkinson's disease and non-motor issues. Neurol. 2008 Sep; 255 Suppl 5():33-8.
39. 41. Lee MA, Prentice WM, Hildreth AJ, Walker RW, Measuring symptom load in Idiopathic Parkinson's disease. Parkinsonism Relat Disord. 2007 Jul; 13(5):284-9.
40. 42. Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H, Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord. 2004 Oct; 19(10):1196-202.
41. 43. Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H, Olfactory loss may be a first sign of idiopathic Parkinson's disease, Mov Disord. 2007 Apr 30; 22(6):83942.
42. 44. Ziemssen T, Reichmann H, Review Non-motor dysfunction in Parkinson's disease, Parkinsonism Relat Disord. 2007 Aug; 13(6):323-32.
43. 45. Chaudhuri KR, Schapira AH, Review Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009 May; 8(5):464-74. 46. Lee MA, Prentice WM, Hildreth AJ, Walker RW, Measuring symptom load in Idiopathic Parkinson's disease. Parkinsonism Relat Disord. 2007 Jul; 13(5):284-9.
44. 47. Goetz CG, Lutge W, Tanner CM, Autonomic dysfunction in Parkinson's disease. Neurology, 1986. 36(1): 73-5.
45. 48. Wittling W, Block B, Genzel S, et al, Hemisphere asymmetry in parasympathetic control of the heart, Neuropsychologia, Vol. 36, No. 5, pp. 461-468, 1998)
46. 49. Erciyas AH, Topalkara K, Topaktaş S et al, Supression of cardiac parasympathetic functions in patients with right hemispheric stroke, European Journal of Neurology 1999, 6: 685-690
47. 50. Avnon Y, Nitzan M, Sprecher E, et al, Autonomic asymmetry in migraine: augmented parasympathetic activation in left unilateral migraineurs, Brain, A Journal of Neurology 2004,Volume 127, Issue 9, pp. 2099-2108
48. 51. Davidson,R. J.and Hugdahl, K (Eds). Brain Asymmetry. MIT-Press, Cambridge, MA, 1995
49. 52. K.Ray Chaudhuri, E. Tolosa (Eds) Parkinson Hastalığının Non-motor Semptomları, Oxford University Press, New York,2009, Bölüm 10, s121-132.
50. 53. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson‘s disease. Arch Neurol 2004; 61: 1906-11.
51. 54. Lang AE,Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004; 3: 309–316
52. 55. Korchounov A, Kessler KR, Yakhno NN, Damulin IV, Schipper H Determinants of autonomic dysfunction in idiopathic Parkinson's disease. J Neurol. 2005;252(12):1530-1536. 217. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson‘s disease. Parkinsonism Related Disorders 2007; 13(Suppl): S2-S7.
53. 56. K. Ray Chaudhuri, Daniel G. Healy, Non-motor symptoms of Parkinson‘s disease: diagnosis and management, Lancet Neurol 2006; 5: 235-45.
54. 57. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson‘s disease. Parkinsonism Related Disorders 2007; 13(Suppl): S2-S7.
55. 58. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta neuropathologica. 2010;119(6):703–13.
56. 59. Chadhuri KR, Martinez-Martin P, Brown RG, et el. The metric properties of a novel non motor symptoms scale for Parkinson‘s disease: Results from an international pilot study. Movement Disorders 2007; 22: 1901- 11.
57. 60. R.P.Munhoz, A.J. Espay et al, Long-duration Parkinson‘s disease: Role of lateralization of motor features , Parkinsonizm and Related Disorders 19 (2013) 77-80.
58. 61. Yust-Katz S, Tesler D, Treves TA, Melamed E, Djaldetti R. Handedness as a predictor of side of onset of Parkinson‘s disease. Parkinsonism Relat Disord 2008;14:633e5.
59. 62. Giardino L (1996) Right-left asymmetry of D-1 and D-2 receptor density is lost in the basal ganglia of old rats. Brain Res 720:235–238.
60. 63. Xu ZC, Ling G, Sahr RN, Neal-Beliveau BS (2005) Asymmetrical changes of dopamine receptors in the striatum after unilateral dopamine depletion. Brain Res 1038(2):163–170.
61. 64. Riederer P, Sian-Hülsmann J, The significans of neuronal lateralization in Parkinson‘s disease, Movement Disorders 2012, 119:953-962.
62. 65. Tomer R, Aharon J, Tsitrinbaum Z, Dopamine asymmetry interacts with medication to affect cognition in Parkinson‘s disease, Neuropsycologia 45 (2007) 357-367.
63. 66. Gasparoli E, Delibori D, Polesello G, Santelli L, Ermani M, Battistin L, Bracco F (2002) Clinical predictors in Parkinson‘s disease. Neurol Sci 23(Suppl. 2):S77–S78.
64. 67. Shinotoh H, Uchida Y, Hisao I, Hattori T (2000) Relationship between striatal [123I]betaCIT binding and four major clinical signs in Parkinson‘s disease. Ann Nucl Med 14:199–203.
65. 68. Huber SJ, Miller H, Bohaska L, Christy JA, Bornstein RA (1992) Asymmetrical cognitive differences associated with hemiparkinsonism. Arch Clin Neuropsychol 7:471–480.
66. 69. Loius ED, Tang MJ, Cote L, Alfaro B, Mejia MA, Marder K (1999) Progression of parkinsonian signs in Parkinson disease. Arch Neurol 56:334–337.
67. 70. Diederich NJ, Fénelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol.2009 Jun;5(6):331–42. doi: 10.1038/nrneurol.2009.62.
68. 71. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson‘s disease. Prevalence, phenomenology and risk factors. Brain. 2000;123(4):733–745.
69. 72. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson‘s disease. Journal of the Neurological Sciences. 2010;289(1-2):12–17.
70. 73. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson‘s disease patients with psychosis. Neurology. 2003;60(11):1756–1761.